TOP TEN perturbations for 38393_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38393_at
Selected probe(set): 202181_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38393_at (202181_at) across 6674 perturbations tested by GENEVESTIGATOR:
lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; basaloid carcinoma; primary)
Relative Expression (log2-ratio):-3.0352478Number of Samples:2 / 3
Experimental | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). | |
Control | lung cancer study 1 (PDX; basaloid carcinoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted). |
stem cell differentiation study 59 (8d) / normal embryonic stem cell sample (WA09)
Relative Expression (log2-ratio):2.967579Number of Samples:4 / 4
Experimental | stem cell differentiation study 59 (8d) |
WA09 embryonic stem cell samples differentiated for 8 days. Further details are described in the paper. | |
Control | normal embryonic stem cell sample (WA09) |
Undifferentiated WA09 embryonic stem cell samples. |
doxorubicin study 3 / untreated MCF-7 cell sample
Relative Expression (log2-ratio):2.7169323Number of Samples:2 / 2
Experimental | doxorubicin study 3 |
MCF7 cells treated with 2uM doxorubicin for 24 hours. ATC code: | |
Control | untreated MCF-7 cell sample |
MCF-7 cells untreated. |
dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)
Relative Expression (log2-ratio):-2.5882473Number of Samples:7 / 8
Experimental | dendritic cell study 6 (gardiquimod) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
Control | dendritic cell study 6 (untreated) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (untreated)
Relative Expression (log2-ratio):-2.566286Number of Samples:4 / 8
Experimental | dendritic cell study 6 (gardiquimod; RN486) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
Control | dendritic cell study 6 (untreated) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
renal cell carcinoma study 10 (PDX; clear cell adenocarcinoma, NOS; metastatic) / renal cell carcinoma study 10 (PDX; clear cell adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):2.5420046Number of Samples:2 / 18
Experimental | renal cell carcinoma study 10 (PDX; clear cell adenocarcinoma, NOS; metastatic) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary clear cell adenocarcinoma, NOS of the kidney (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
Control | renal cell carcinoma study 10 (PDX; clear cell adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the kidney (subcutaneously implanted). |
stem cell differentiation study 59 (iDRG; 9d) / normal embryonic stem cell sample (WA09)
Relative Expression (log2-ratio):2.475834Number of Samples:4 / 4
Experimental | stem cell differentiation study 59 (iDRG; 9d) |
Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 1 day. Further details are described in the paper. | |
Control | normal embryonic stem cell sample (WA09) |
Undifferentiated WA09 embryonic stem cell samples. |
brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample
Relative Expression (log2-ratio):2.3885107Number of Samples:3 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) |
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated HCT 116 DICER1(-/-) cell sample |
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
FoxO3 H212R overexpr. study 1 / FoxO3 overexpr. study 1
Relative Expression (log2-ratio):2.2918053Number of Samples:3 / 3
Experimental | FoxO3 H212R overexpr. study 1 |
Human umbilical vein endothelial cells (HUVECs) transfected with retroviral pBP FoxO3.A3.ER.H212R vector for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression of mutated FoxO3 (forkhead box O3) H212R, treated with 4OHT for 12 hours. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, treated for 12 hours with 4OHT, and harvested for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments. ATC code:--- | |
Control | FoxO3 overexpr. study 1 |
Human umbilical vein endothelial cells (HUVECs) transfected with retroviral pBP-FoxO3.A3.ER vector for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression of FoxO3 (forkhead box O3), treated with 4OHT for 12 hours. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, treated for 12 hours with 4OHT, and harvested for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments. ATC code:--- |
brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):2.284277Number of Samples:3 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated HCT 116 cell sample |
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |